Dewpoint Therapeutics selects groundbreaking MYC development candidate
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Over 8.8?million Indians aged 60 and above currently live with dementia,
Subscribe To Our Newsletter & Stay Updated